LACTB and COVID-19: Before matching, standardized differences >0.10 between procalcitonin-tested and nontested patients were observed for several clinical characteristics, including intensive care unit status (35.7% vs 14.3%), diagnosis of community-acquired pneumonia (80.7% vs 64.7%) or hospital-acquired pneumonia (8.5% vs 4.1%), positive test for COVID-19 (10.3% vs 1.1%), and treatment with a cephalosporin (43.8% vs 35.4%), beta-lactam/beta-lactamase inhibitor combination (33.2% vs 23.2%), or glycopeptide (24.3% vs 10.4%) antibiotic.